COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacay of Chloroquine in COVID-19 Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04353336
Recruitment Status : Not yet recruiting
First Posted : April 20, 2020
Last Update Posted : April 20, 2020
Information provided by (Responsible Party):
Sherief Abd-Elsalam, Tanta University

Brief Summary:
Chloroquine in COVID-19 treatment

Condition or disease Intervention/treatment Phase
COVID-19 Coronavirus Infection Drug: Chloroquine Phase 2 Phase 3

Detailed Description:
Clinical Study Evaluating the Efficacy of Chloroquine in COVID-19 treatment

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Study Evaluating the Efficacy of Chloroquine in COVID-19 Treatment
Estimated Study Start Date : April 17, 2020
Estimated Primary Completion Date : December 1, 2030
Estimated Study Completion Date : December 1, 2030

Arm Intervention/treatment
Experimental: Chloroquine
Chloroquine treatment
Drug: Chloroquine
Other Name: alexoquine, chloroquine

No Intervention: No intervention
no intervention

Primary Outcome Measures :
  1. Number of patients with virological cure [ Time Frame: 6 months ]
    the number of patients with virological cure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Covid 19 patients

Exclusion Criteria:

  • Allergy or contraindication to the drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04353336

Layout table for location contacts
Contact: Sherief Abd-Elsalam, ass. prof. 00201147773440

Layout table for location information
Tanta University
Tanta, Egypt, 35111
Sponsors and Collaborators
Tanta University
Layout table for investigator information
Principal Investigator: sherief Abd-Elsalam, Ass. Prof. Tanta University - Faculty of Medicine
Layout table for additonal information
Responsible Party: Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine, Tanta University Identifier: NCT04353336    
Other Study ID Numbers: chloroquine covid
First Posted: April 20, 2020    Key Record Dates
Last Update Posted: April 20, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Severe Acute Respiratory Syndrome
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Chloroquine diphosphate
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Antirheumatic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antinematodal Agents